Hemochromatosis (Iron Overload) Disease Treatment Market Report 2026

Hemochromatosis (Iron Overload) Disease Treatment Market Overview

• Hemochromatosis (Iron Overload) Disease Treatment market size has reached to $28.62 billion in 2025 • Expected to grow to $34.8 billion in 2030 at a compound annual growth rate (CAGR) of 4.2% • Growth Driver: Hemochromatosis Treatment Market Thrives Amid Escalating Stressful Lifestyles • Market Trend: Key Approvals Drive Growth In Hemochromatosis Treatment Market With Deferiprone Leading The Charge In Managing Iron Overload • North America was the largest region in 2025.

What Is Covered Under Hemochromatosis (Iron Overload) Disease Treatment Market?

Hemochromatosis is a genetic disorder characterized by the excessive absorption and storage of iron in the body, including the liver, heart, pancreas, and joints, which can result in serious health complications. The treatment aims to manage iron levels and prevent complications with the help of early detection of the disease. The main types of hemochromatosis (iron overload) disease are hereditary hemochromatosis and acquired hemochromatosis. Hereditary hemochromatosis (HH) is a genetic disorder characterized by the excessive absorption and accumulation of iron in the body. The various treatments include therapeutic phlebotomy, iron chelation therapy, and others that are used by various end-users such as hospitals, surgical centers, and others.

What Is The Hemochromatosis (Iron Overload) Disease Treatment Market Growth Forecast?

The hemochromatosis (iron overload) disease treatment market size is expected to see steady growth in the next few years. It will grow to $34.8 billion in 2030 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to increasing adoption of personalized treatment strategies, rising demand for non-invasive monitoring tools, expansion of genetic counseling services, growing focus on early intervention, increasing research into novel therapies. Major trends in the forecast period include increasing emphasis on early genetic screening, rising adoption of therapeutic phlebotomy protocols, growing use of iron chelation therapies, expansion of disease awareness programs, enhanced focus on long-term disease management.

Global Hemochromatosis (Iron Overload) Disease Treatment Market Segmentation

1) By Type: Hereditary Hemochromatosis, Acquired Hemochromatosis 2) By Treatment: Therapeutic Phlebotomy, Iron Chelation Therapy, Other Treatments 3) By End-Users: Hospitals, Surgical Centers, Other End-Users Subsegments: 1) By Hereditary Hemochromatosis: Genetic Counseling, Phlebotomy, Chelation Therapy 2) By Acquired Hemochromatosis: Treatment Of Underlying Conditions, Phlebotomy, Chelation Therapy

What Is The Driver Of The Hemochromatosis (Iron Overload) Disease Treatment Market?

The increasingly stressful lifestyle is expected to propel the growth of the hemochromatosis (iron overload) disease treatment market going forward. Stressful lifestyles profoundly impact a person's physical and mental health, and prolonged exposure to high-stress levels may lead to a range of health issues, including hemochromatosis (iron overload) disease. The treatment of hemochromatosis, a condition characterized by iron overload in the body, not only addresses the physical aspects of the disease but also plays a vital role in reducing the emotional and psychological stress that often accompanies managing a chronic health condition. For instance, in November 2025, according to the American Psychiatric Association, a US-based professional organization of psychiatrists and trainee psychiatrists, among U.S. adults, 41% say they anticipate more stress related to the holidays this year than last year, a notable increase over 2024 (28%) and 2023 (29%). Therefore, increasing stressful lifestyle drives the hemochromatosis (iron overload) disease treatment industry.

Key Players In The Global Hemochromatosis (Iron Overload) Disease Treatment Market

Major companies operating in the hemochromatosis (iron overload) disease treatment market are Pfizer Inc., AbbVie Inc., Novartis AG, Merck KGaA, Sanofi SA, Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Roche Holding AG, Abbott Laboratories, Fresenius Kabi AG, Apotex Inc., Teva Pharmaceutical Industries Ltd., Recordati S.p.A., Chiesi Farmaceutici S.p.A., Ionis Pharmaceuticals Inc., Silence Therapeutics, DisperSol Technologies LLC., Hinoman Ltd., Pharmacosmos A/S

Global Hemochromatosis (Iron Overload) Disease Treatment Market Trends and Insights

Major companies operating in the hemochromatosis (iron overload) disease treatment market receive approvals of drugs such as deferiprone for patients experiencing transfusional iron overload to help reduce excess iron levels in the body and prevent complications associated with iron accumulation, such as organ damage. Deferiprone refers to a medication used to treat iron overload in individuals who have received numerous blood transfusions, commonly seen in conditions such as thalassemia, sickle cell anemia, or other chronic anemias. For instance, in March 2023, Chiesi Global Rare Diseases Inc, a US-based business unit, announced the approval of FERRIPROX MR (deferiprone) extended-release tablets in Canada. FERRIPROX MR is indicated for the treatment of transfusional iron overload in patients with thalassemia syndromes when current chelation therapy is inadequate. Patients with sickle cell disease (SCD) or other types of anemia. Deferiprone is an orally active iron-chelating agent that effectively reduces iron concentration in the body by penetrating cell membranes and binding to excess iron, facilitating its removal from organs and tissues.

What Are Latest Mergers And Acquisitions In The Hemochromatosis (Iron Overload) Disease Treatment Market?

In January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, entered into a worldwide license and collaboration agreement with Protagonist Therapeutics, Inc., for Rusfertide, a late-stage rare hematology asset. The collaboration aims to advance the development and commercialization of Rusfertide for patients with rare hematologic disorders, including those affected by iron overload conditions, enhancing treatment options while fostering innovation in the rare disease therapeutics market. Protagonist Therapeutics, Inc. is a US-based biotechnology company focused on developing peptide-based therapies for serious and rare diseases.

Regional Outlook

North America was the largest region in the hemochromatosis (Iron Overload) disease treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hemochromatosis (Iron Overload) Disease Treatment Market?

The hemochromatosis (iron overload) disease treatment market consists of revenues earned by entities by providing genetic testing services, transplantation services, and blood testing and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemochromatosis (iron overload) disease treatment market also consists of sales of vitamin C supplements, blood pressure drugs, and iron-free supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hemochromatosis (Iron Overload) Disease Treatment Market Report 2026?

The hemochromatosis (iron overload) disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hemochromatosis (iron overload) disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.